What could possibly go wrong with prioritising shareholder returns over investment in R&D and product development? That $25,000,000,000+ they had lying around to spend on stock buybacks in the last two years alone definitely couldn't have been used any better ($4B in Q1 2020, $13B in 2019, $10B in 2018).
Biting the hand that feeds IT
